Warning letter
Lincare, Inc.: warning letter of Apr 25, 2016
FDA warning letter 492840 · Dallas District Office
Key facts
| Reference number | 492840 |
|---|---|
| Company | Lincare, Inc. |
| Subject | Total Parenteral Nutrition (TPN) Drug Products/Adulterated |
| Issue date | Apr 25, 2016 |
| Posted date | May 16, 2016 |
| Issuing office | Dallas District Office |
| Product type | Drugs |
| Inspection city | North Little Rock |
| Inspection ZIP | 72113 |
| Inspection start date | Jun 1, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: